Search research articles
Contact Us
Filters
Showing results (71-80 of 143) with videos related to
Page
of 15
Sort By:
Journal of Experimental & Clinical Cancer Research : CR
|
February 19, 2025
Highlighting recent achievements to advance more effective cancer immunotherapy
Beatrice Belmonte, Sheila Spada, Paola Allavena, et al.
Cancers
|
December 29, 2019
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti, Francesca Ligorio, Emma Zattarin, et al.
Expert Review of Anticancer Therapy
|
July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Julieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
Clinical Lung Cancer
|
August 27, 2024
The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment
Chiara Bennati, Roberto Ferrara, Sabina Sangaletti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 10, 2024
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
Daniele Marinelli, Antonio Nuccio, Alessandro Di Federico, et al.
Journal for Immunotherapy of Cancer
|
February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
Boris Duchemann, Marie Naigeon, Edouard Auclin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 19, 2019
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
Giulia Galli, Alessandro De Toma, Filippo Pagani, et al.
European Journal of Internal Medicine
|
August 15, 2021
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
Frontiers in Oncology
|
June 27, 2022
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2021
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis
Francesco Passiglia, Michela Cinquini, Luca Bertolaccini, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 143) with videos related to
Sort By:
Page
of 15
Journal of Experimental & Clinical Cancer Research : CR
|
February 19, 2025
Highlighting recent achievements to advance more effective cancer immunotherapy
Beatrice Belmonte, Sheila Spada, Paola Allavena, et al.
Cancers
|
December 29, 2019
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti, Francesca Ligorio, Emma Zattarin, et al.
Expert Review of Anticancer Therapy
|
July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Julieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
Clinical Lung Cancer
|
August 27, 2024
The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment
Chiara Bennati, Roberto Ferrara, Sabina Sangaletti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 10, 2024
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
Daniele Marinelli, Antonio Nuccio, Alessandro Di Federico, et al.
Journal for Immunotherapy of Cancer
|
February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
Boris Duchemann, Marie Naigeon, Edouard Auclin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 19, 2019
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
Giulia Galli, Alessandro De Toma, Filippo Pagani, et al.
European Journal of Internal Medicine
|
August 15, 2021
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
Frontiers in Oncology
|
June 27, 2022
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2021
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis
Francesco Passiglia, Michela Cinquini, Luca Bertolaccini, et al.
Page
of 15